Announcements - OBI Pharma 台灣浩鼎

2022.Feb.08

Announcement of preclinical animal study results of OBI’s COVID-19 vaccine

2022.Jan.28

The Active Cancer Immunotherapy OBI-822, has been granted by URPL of Poland to proceed to Phase III Clinical Trial

2022.Jan.25

Announcement of reference date of 2022 cash capital increase and share subscription

2022.Jan.25

The Active Cancer Immunotherapy OBI-822, has been granted by AEMPS of Spain to proceed to Phase III Clinical Trial

2021.Dec.18

The Active Cancer Immunotherapy OBI-822, has been granted by DIGEMID of Peru to proceed to Phase III clinical trial

2021.Dec.15

OBI has filed the application for a Phase II clinical trial for OBI-833, an active cancer immunotherapy, to TFDA

2021.Dec.08

OBI in-licensed “anti-Trop2 antibody” exclusive rights from Biosion

2021.Dec.03

The Active Cancer Immunotherapy OBI-822, has been granted by COFEPRIS of Mexico to proceed to Phase III Human Clinical Study

2021.Nov.30

Announcement on behalf of subsidiary, OBIGEN, that OBI-858 completes its Phase I and demonstrates good safety, proceeding to Phase II as planned

2021.Nov.26

OBI’s BOD resolved to in-license a preclinical project from a biotech company specialized in novel cancer therapies

News

Latest News

Events

Latest events